LPCN 1154A not checked

Lipocine Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
3 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
Tested for
Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression, Post-Natal Depression, Peripartum Depression
Main trialPhase 3
“The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause”In the company’s words, NCT07822321 on ClinicalTrials.gov
Other names
Brexanolone

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Aug 2027 Brexanolone Lifting Outcomes Of Moms
Phase 3Completed 16 Jan 2026 A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD
Phase 1Ended not given A Randomized, Double-blind, Double Placebo-controlled, 4-Period Crossover Study to Evaluate the Central Nervous System Pharmacodynamic Activity of Brexanolone Using Transcranial Magnetic Stimulation in Healthy Male Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LPCN 1154A

Following is part of Solo: you see every change to LPCN 1154A the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in